FDA Targets Hims & Hers, Other Marketers of Unapproved GLP-1 Weight-Loss Drugs
The FDA said it would take "decisive steps" to restrict non-approved drugs that use GLP-1 active pharmaceutical ingredients.
----
Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe
As it probes bids for Warner, the department is asking if the streamer has engaged in conduct that could make it a monopoly.
----
SpaceX Delays Mars Plans To Focus on Moon
Elon Musk's rocket company had aimed to reach the red planet in 2026
----
Jeep Maker Stellantis Books $26 Billion Charges in EV Reset
The charges are the most costly yet reported by an automaker related to bad bets on EVs. The company's Europe-listed shares fell more than 20%.
----
Hobbit-Inspired Startup Becomes First New Bank Greenlighted by Trump 2.0
Erebor founder Palmer Luckey was one of the tech industry's early Trump supporters and is known for his penchant for Hawaiian shirts.
----
Carlyle Profit Rises as Management Signals Minimal Hit from Software Turmoil
Software 'is not a piston in the engine' of the firm's growth, executives say, noting it represents 6% of assets under management.
----
Toyota Replaces CEO After $9 Billion Hit From Trump's Tariffs
The Japanese automaker said Chief Financial Officer Kenta Kon will become the new CEO.
----
Uber Ordered to Pay $8.5 Million in Passenger Sexual Assault Case
A jury found the company liable for the 2023 sexual assault of a 19-year-old passenger.
----
Newell Brands to Lower Some Prices Following Resistance to Hikes
Newell Brands reported lower fourth-quarter sales after previously saying that its price hikes were drawing resistance from customers.
----
Philip Morris Leans Into Smoke-Free to Fuel Growth
The tobacco company said its smoke-free business last year accounted for about 42% of revenue, or nearly $17 billion.
----
AutoNation Revenue Declines on Weaker New, Used Vehicle Sales
AutoNation reported lower fourth-quarter revenue, weighed down by fewer comparable sales of both new and used vehicles.
----
Under Armour Lifts Outlook Despite Tariff Pressures
Under Armour expects revenue to fall at the milder end of its fiscal 2026 forecast, even as weak demand in its key North American and Asia-Pacific markets and tariff pressures persist into the new year.
----
Biogen Revenue Down as Multiple Sclerosis Sales Slide
Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.
----
FAT Brands Bondholders Seek CEO Ouster Over 'Mystery' Stock Sale
Bankrupt company behind Fatburger and Johnny Rockets sought court approval for the stock sale after the transaction had already taken place.
----
Centene Swings to Loss Despite Higher Revenue
Centene swung to a fourth-quarter loss despite logging higher revenue, as the company continues working to restore profitability and stabilize its Medicaid business.
----
Trump's New Tax Law Saved Amazon Billions
Breaks for investment and research lowered the company's payments to the U.S. government.
----
Orsted Shares Rise After Guidance Confirmation Despite Blow From U.S. Disruption
The company confirmed earnings guidance for the next two years despite hefty impairments and U.S. tariff costs hitting its bottom line in 2025.
(END) Dow Jones Newswires
February 06, 2026 19:00 ET (00:00 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.